• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A sensitized particulate reagent for immunological reaction, which comprises particulate carriers suspended in an aqueous medium having an electric conductivity of 5.0 mS/cm or less, said particulate carriers being sensitized with an antigen or an antibody.
    公开号:SU1431662A3
    申请号:SU823430146
    申请日:1982-05-03
    公开日:1988-10-15
    发明作者:Тсутсуй Сатоси；Судо Тадамитсу；Ито Митио
    申请人:Мицубиси Кемикал Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    Nliili
    WITH
    oh oh
    The invention relates to an immunochemical reagent, and can be used in medicine, biochemistry, hygiene and epidemiology in the analysis of trace amounts of compounds, especially antigens and antibodies.
    The purpose of the invention is to increase the sensitivity of the reagent.
    The method is carried out in the following way | Q.
    The carrier particles, which constitute part of the reagent according to this invention, are practically insoluble particles in an aqueous jj medium. Such carrier particles can be made from any suitable compound that includes latexes of such polymeric compounds, such as polystyrene, butadiene-20-copolymer, polyacrylate, polyacrylate, acrylonitrile copolymer with butadiene and styrene, the latexes of these polymers activated by the introduction of carboxyl or anide groups by copolymerization with acrylic acid, methacrylic acid, acrylamide, and the like. blood cells, bacteria such as staphylococci and streptococci, serratue marcescens, rickettsia, and the JQ portions of these bacteria.
    The average particle diameter of the carriers is from 0.05 to J, 2 μm, or from 0.1 to 1.00 μm, preferably from 0.2 to 0.8 μm. If the particle diameter of the support is too large, then the limits of analysis are narrowed or become more unstable. On the other hand, particles with a small diameter of the carrier lead to economic losses upon receipt of the reagent and have a low sensitivity. Consequently, particles with both an excessively large and an excessively small p. diameters should not be used .45
    Antigens applied to the carrier particles of the reagent of this invention include, for example, proteins, polypeptides, steroids, polysaccharides, lipids, pollen, dust, haptens, and the like. Antibodies include, for example, proteins produced by reaction with these IT genes.
    The concentration of the carrier particles is usually 0.03-0.3%, preferably 0.05-0.2% (final concentration concentration). At a higher concentration of carrier particles, it is necessary to use more complex equipment.
    Q
    j 0 5 Q
    five
    five
    no analysis with the reagent of the present invention, with no further increase in efficiency being achieved. At low particle concentrations, satisfactory sensitivity and reactivity are not obtained.
    The carrier particles can be sensitized with an antigen or antibody by any known method, i.e. physical adsorption of the antigen or antibody on the carrier particles, the chemical binding of the antigen or antibody to the carrier particles, or a combination of these methods.
    The amount of antigen or antibody to sensitize the carrier is selected depending on the specific type of antigen or antibody and the desired accuracy of the analysis using this reagent.
    The carrier particles that are sensitized with an antigen or antibody can be treated with a stabilizer, including amino acids, polypeptides, proteins, etc., that are not deposited in this immunological reaction, before suspension in an aqueous medium, and it is preferable to use serum albumin as a stabilizer. The treatment with a stabilizer is preferably carried out in a known manner, in terms of storage and stability of the reaction. A particularly significant effect is achieved in cases where the antigen or antibody is physically adsorbed onto the carrier.
    The aqueous medium in which the carrier is suspended, sensitized with an antigen or antibody, should have an electrical conductivity of 5.0 or 2.5 ms / cm, preferably 1.0 ms / cm and below. With an electrical conductivity exceeding 5.0 ms / cm, the reagent is unstable, which leads to a decrease in the accuracy of the analysis.
    The aqueous medium may be water, a buffer solution, and the like. and contain one or more additives selected from stabilizers, preservatives, chelating agents, surface active compounds, etc. Buffer solutions include glycine buffers, phosphoric acid based buffers, citrate buffers, barbital buffers, borate buffers, buffers based on the tris (tris) hydroxymethyl (anino methane) salt of acid, tris-malate buffers, ammonium buffers, etc.
    Stabilizers include, for example, said stabilizers in concentrations of 0.001-1%, preferably 0.05-0.6%.
    Suggested preservatives include merthiolate and sodium azide.
    Ethylene diaminetetraacetic acid, NITRILTRI-CUTNIC acid, CIC LO- are used as chelating agents.
    hexanediaminetetraacetic acid and the like, non-ionic surfactants as surface-active compounds.
    The pH of the aqueous medium is 5-10 or 6-9.5, preferably 6.5-8.5. If the pH of the aqueous medium is less than 5, the reagent is unstable, although the sensitivity is increased. An aqueous medium having a pH value greater than 10 leads to a decrease in sensitivity and in some cases to the instability of the storage of the reagent.
    Particles of the carrier sensitized with an antigen or antibody are suspended in an aqueous medium at a concentration of 0.01-20%, preferably 0.05-10%. At lower or higher concentrations, the resulting reagent has a lower stability, its use becomes inconvenient and limited.
    The proposed reagent is obtained by sensitizing the described carrier particles with an antigen and an antibody in a known manner, followed by treating the sensitized carrier with a stabilizer and suspending the carrier in an aqueous medium in a known manner.
    The reagent according to the present invention is suitable as a reagent or basic reagent solution for carrying out a reaction on a glass plate or in a test tube with visual observation of agglutination or when conducting a reaction in an optical cell with optical control over the course of the reaction.
    The reagent can be used to analyze an immunological response. For this, the proposed reagent is diluted with a buffer solution and the concentration of the carrier sensitized with an antigen or antibody is adjusted to a level suitable for the analysis of an immunological reaction.
    The concentration of the reagent depends on the type of antibody or antigen being analyzed, their concentration and reaction.

    5 o
    0 5
    0 5
    five
    ability, which is determined experimentally. In the case of an optical change in the immunological reaction, the final concentration of the carrier is at least 0.03 wt.% Or from 0.05 to 1 wt.% And more, preferably 0.1-0.5 wt.%.
    In the case of visual observation of an immunological reaction, the resultant concentration is in the range from 0.05 to 0.8% by weight, preferably from 0 to 0.5% by weight.
    Buffer solutions that can be used to dilute the reagent include glycine buffers, borate buffers, trihydrochloric acid buffers, tris-maple buffers, ammonium buffers, and the like.
    The pH of the buffer solutions used is 7.6-9.6, preferably.8.0-9.0. A buffer solution with lower pH values agglutinates and, therefore, makes the reagent unsuitable, although it results in increased sensitivity. At higher pH, sensitivity is reduced and properties may be affected when stored at elevated temperatures, which is undesirable.
    Thus, upon visual observation of an immunological reaction, a predetermined amount of reagents and a sample containing an antigen or antibody are mixed on a glass plate or in a test tube and the agglutination of the sensitized particles is observed.
    In the case of an optical measurement of an immunological reaction, a predetermined amount of a reagent and a sample containing an antigen or antibody are mixed and the change in light transmission, light scattering or opacification is measured and determined in an optical cell.
    If the optical measurement is carried out by determining the light transmission, then usually light with a wavelength greater than the average diameter of the carrier particles is used, with a ratio of wavelength to particle diameter of at least 1.1 or at least 1.5 and preferably at least 2. Length The wavelength is usually in the range of from 600 to 2400 nm, preferably from 800 to 1800 nm. If the light has a shorter length, it is necessary to use carrier particles of sufficiently low concentration, as well as a reagent having extremely high dispersibility, in order to obtain a suitable light transmission, which makes it difficult to increase sensitivity and in some cases to a reversible reaction. A longer wavelength is also undesirable due to a decrease in sensitivity. Light can be either monochromatic or IQ or polychromatic. The optical cuvette used to measure light transmission has a thickness of 0.2 to 10 mm.
    The measurement of the transmission can be carried out by determining the time required to achieve a given absorption value, or by determining the increase in absorption over a certain period of time, 7 °
    Optical measurement using light scattering is carried out as in the determination of light transmission.
    The proposed reagents are 25 sensitized reagent particles for use in immunological reactions. With their help, the amounts of antigen or antibody in various samples can be determined with good reproducibility and high accuracy. In addition, they are effective after freezing and thawing and, therefore, can be lyophilized and reused. five
    The method is illustrated by the following examples.
    An example of a "Globulin antibody, anti-c-fetoprotein, is dissolved in Ofi M glycine buffer (pH 8.3). Globulin antibodies correspond to 800–1500 for each latex particle (having a diameter of 0.052 µm, manufactured by Dow Chemical). Then the solution is mixed with an equal volume of latex– glycine buffer (pH 8.8 with stirring and room temperature to achieve adequate sensitization A) "After separation by centrifugation, the supernatant is removed and the precipitate is processed-gg is watered with the appropriate amount of bovine serum albumin. The thus-obtained sensitized particles are suspended in a buffer solution with a concentration of particles 1.0%, HMe-gg electrically conducting, i, 5 ms / cm and containing an appropriate amount of onservant, after which the suspension is stored, With the resulting
    the reagent achieves excellent analysis accuracy.
    For analysis of the immunological reaction, the reagent is diluted with glycine buffer (pH 8.6).
    The results of the analysis are presented in the table.
    Note. Values in brackets are obtained by radioimmunoassay,
    PRI me R 2 Antibody anti-CRP (C-reactive protein) is dissolved in 0.2 M borate buffer (pH 8.8) and latex particles (diameter 0.220 µm, manufactured by Dow Chemical) suspended in such buffer, Sensitize with the resulting solution so that each particle carries 800–1800 antigens on itself, Sensitized latex particles are treated with bovine serum albumin and suspended in the appropriate amount of borate buffer (4.0 ms / cm) with a particle concentration of 2.0%. The resulting reagent has a very high measurement accuracy.
    Example 3. Antibody F (ab) 2 rat or goat anti-human fibrinogen antibody is dissolved in O, 1 M tris-malate buffer (pH 8.6), and latex particles (diameter 1.091 µm, manufactured by Dow Chemical) are suspended baths in the same buffer are sensitized with the resulting solution so that the sensitivity of the resultant reagent is equal to the order value
    the solution used to ultimately suspend the sensitized particles has a conductivity of approximately 0.5-0.8 ms / cm,
    PRI me R 6, Latex particles are sensitized with a highly purified rat antibody against human
    IgM in glycine buffer with pH 9.6. Quantitative ratios vary depending on the quality of the antibodies and on the desired sensitivity. Sensitized particles are treated with an appropriate amount of bovine serum albumin and then suspended in an aqueous solution having a conductivity equal to approximately
    1.2 ms / cm, which may contain about 0.05% bovine syrup 100 ng / ml. Then the particles are treated with 20 exact albumin, as a result of which bovine serum albumin and sus-get the target reagent with concentration — pendiate in an aqueous solution containing 0.1% sodium azide (1.0 ms / cm) at a particle concentration of 0.01%, When used, the reagent is diluted with Tris-Mathlate buffer (pH 8.4) or Tris-hydrochloric acid buffer (pH 8.4) to the desired latex concentration and the npoBOj HT reaction on the glass plate or the reagent can be used in 30 seconds without dilution for optical analysis. When reacting on a glass plate using this reagent, agglutinating and nonagglutinating systems are distinguished.
    Example 4, Globulin anti-human goat antibody is dissolved in 0.1 M tris-malate buffer (pH 8.8) and latex particles are sensitized with a solution (0.312 µm in diameter, 40 are prepared under the conditions of Example 7, for the manufacture of Dow Chemical), suspended except that antidized are used in the same buffer. Sensi is a human igg antibody f (ab) .j and
    particles of 2.5%.
    Example. Highly purified rat anti-hCG F (ab) i antibody was dissolved in 0.2 M tpc-HC1 buffer (pH 8.6) and the resulting solution was used to sensitize latex particles (0.220 µm in diameter, manufactured by Dow Chemical) suspended in the same buffer at room temperature. After treatment with an appropriate amount of bovine serum albumin, the sensitized particles are suspended in an aqueous solution having a conductivity of approximately 0.8 ms / cm and a concentration of particles of 1%, and then stored,
    PRI me R 8. Latex reagent
    latex particles having a diameter of 0.089 µm (Dow Chemica 45 production; latex concentration is 0.25%. The resulting reagent shows good accuracy of analysis,
    PR and M 9, Latex reagent receive in the conditions of example 7 for use
    The bilized particles are then treated with bovine serum albumin and finally suspended in an aqueous solution with a particle concentration of 2%, having a conductivity of approximately 3.0 ms / cm. When used, the suspension is diluted with 0, J M Tris-malate or Tris-HC buffer to the required 50 with a treatment that uses anticoncentration or is used alone.
    PRI and MER 5. Rat antibody F (ab) 2 against human IgA is dissolved in 0.2 M borate buffer (pK 8.3), the solution is also treated,
    as in example 4, and get the target reagent in suspension with a concentration of 1% with the exception that water
    cea (carcinogenic antigen) titel f (ab) and latex particles. having a diameter of 0.8 µm (manufactured by Dow Chemical), the latex concentration of 55 is 1%, the resulting reagent achieves good analysis accuracy,
    Example 0, Latex reagent for analysis in (-fept protein, I obtain according to the procedure described in Example J,
    the solution used to ultimately suspend the sensitized particles has a conductivity of approximately 0.5-0.8 ms / cm,
    PRI me R 6, Latex particles are sensitized with a highly purified rat antibody against human
    IgM in glycine buffer with pH 9.6. Quantitative ratios vary depending on the quality of the antibodies and on the desired sensitivity. Sensitized particles are treated with an appropriate amount of bovine serum albumin and then suspended in an aqueous solution having a conductivity equal to approximately
    1.2 ms / cm, which may contain approximately 0.05% bovine serum albumin, as a result of which the target reagent is obtained with a concentration of
    is prepared under the conditions of Example 7, except that the anti-human igg antibody f (ab) .j and
    particles of 2.5%.
    Example. Highly purified rat anti-hCG F (ab) i antibody was dissolved in 0.2 M tpc-HC1 buffer (pH 8.6) and the resulting solution was used to sensitize latex particles (0.220 µm in diameter, manufactured by Dow Chemical) suspended in the same buffer at room temperature. After treatment with an appropriate amount of bovine serum albumin, the sensitized particles are suspended in an aqueous solution having a conductivity of approximately 0.8 ms / cm and a concentration of particles of 1%, and then stored,
    PRI me R 8. Latex reagent
    latex particles having a diameter of 0.089 µm (manufactured by Dow Chemical), 45 The latex concentration is 0.25%. The resulting reagent shows good accuracy of analysis,
    PRA and MER 9, Latex reagent is prepared under the conditions of Example 7 for eliminating the use of antisera (carcinogenic antigen) f (ab) antibody and latex particles having a diameter of 0.8 µm (manufactured by Dow Chemical), Concentration latex is 1%, the resulting reagent shows good accuracy of analysis,
    Example 0 Latex reagent for analysis in (-fept protein is prepared according to the procedure described in Example J,
    with the exception that the conductivity is adjusted to 5 mΩ / cm, the resulting reagent shows good accuracy of analysis.
    Example 1J, The procedure of Example I is repeated using 1.20 µm latex particles. Reagent shows high measurement accuracy
    Example 2. The procedure used in Example 2 was repeated, using a buffer medium whose conductivity was 2.5 / cm. The reagent shows a high accuracy of measurements,
    Thus, the proposed reagent is highly sensitive in detecting antigens and antibodies, approaching sensitivity to radioimmunoassay.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    A method of producing a reagent for carrying out an agglutination reaction, including sensitizing the carrier particles with an antigen or an antibody, and suspended in an aqueous medium, characterized in that, in order to increase the sensitivity of the reagent, carrier particles with a size of 0.052-1.2 µm and suspension are used to sensitize Pending is carried out in a medium with an electrical conductivity of 5.0 ms / cm and less and with a particle concentration of 0.01-20%.
    类似技术:
    公开号 | 公开日 | 专利标题
    US4305925A|1981-12-15|Latex reagent
    AU614109B2|1991-08-22|Test method and reagent kit therefor
    US4241176A|1980-12-23|Magnetic gel suitable to immunoenzymatic determinations
    US4118192A|1978-10-03|Method and apparatus for the measurement of antigens and antibodies
    US4205954A|1980-06-03|Kinetic latex agglutinometry
    US4292038A|1981-09-29|Formamide-containing latex agglutinating reagent for immunoassay
    US4332788A|1982-06-01|Method of determining an antigen, antibody for antigen-antibody complex including fixing the aggregates thereof
    SU1431662A3|1988-10-15|Method of producing reagent for effecting agglutination reaction
    JPH0616044B2|1994-03-02|Immunological latex agglutination method
    US4052504A|1977-10-04|Assay for thyroxine binding globulin
    JP3623657B2|2005-02-23|Nonspecific reaction inhibitor, immunoassay reagent and immunoassay method
    CA1049404A|1979-02-27|Modified blood cells as carriers in immunochemical measurement
    JP3220546B2|2001-10-22|Method for measuring antigen or antibody in the presence of immune complex
    US4792527A|1988-12-20|Method of assaying biologically active substances and labelling agents therefor
    US4350677A|1982-09-21|Reagent for optimizing agglutination
    JP2682697B2|1997-11-26|Immunoassay reagents and immunoassays
    JPH1123573A|1999-01-29|Immunological measuring method
    JP4278123B2|2009-06-10|Immunological measurement method, immune reaction interfering substance removal method and measurement reagent
    JPH09304386A|1997-11-28|Manufacture of immunity diagnostic drug and immunity diagnostic drug obtained
    Masson1987|Particle counting immunoassay—an overview
    JPH0712818A|1995-01-17|Immunological detection
    AU619179B2|1992-01-23|Method for the quantitative determination of serum proteins in body fluids and agents for carrying out the process
    JPH09101307A|1997-04-15|Method for detecting or measuring immunologically reactive substance
    CA1057194A|1979-06-26|C1q in immunochemical determination
    JP3968287B2|2007-08-29|Immunoassay method
    同族专利:
    公开号 | 公开日
    DK157109B|1989-11-06|
    KR900002347B1|1990-04-12|
    DE3265562D1|1985-09-26|
    DK190582A|1982-11-03|
    JPS57182168A|1982-11-09|
    CS312082A2|1985-08-15|
    AT15107T|1985-09-15|
    AU8282482A|1982-11-11|
    ES511798A0|1983-12-01|
    NO821448L|1982-11-03|
    ES8401260A1|1983-12-01|
    AU550925B2|1986-04-10|
    JPS6367865B2|1988-12-27|
    ZA822727B|1983-11-30|
    PT74834B|1983-10-28|
    EP0064275B1|1985-08-21|
    DD204313A5|1983-11-23|
    NO159964C|1989-02-22|
    CA1186222A|1985-04-30|
    KR830010385A|1983-12-30|
    EP0064275A1|1982-11-10|
    DK157109C|1990-04-09|
    PT74834A|1982-05-01|
    IL65648D0|1982-07-30|
    HU186928B|1985-10-28|
    NO159964B|1988-11-14|
    CS241506B2|1986-03-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1362776A|1970-07-17|1974-08-07|Wellcome Found|Immunological reagent|
    US3857931A|1971-02-01|1974-12-31|Hoffmann La Roche|Latex polymer reagents for diagnostic tests|
    JPS5811575B2|1976-08-16|1983-03-03|Teikoku Zoki Seiyaku Kk|
    US4092114A|1976-10-20|1978-05-30|Fisher Scientific Company|Indirect latex test for determination of immunoglobulins|
    IT1087285B|1976-11-10|1985-06-04|Hoffmann La Roche|IMMUNOLOGICAL DETERMINATION PROCEDURE|
    FR2399448B1|1977-08-03|1981-10-23|Rhone Poulenc Ind|
    EP0001223A3|1977-09-19|1979-12-12|F.Hoffmann-La Roche & Co. Aktiengesellschaft|Latex coated with a polyhydroxy compound, process for the preparation of this latex, immunological reagent containing this latex, process for the preparation of this reagent, application of this reagent, testing procedure utilising this reagent and reagent kit containing this reagent|
    GB2013211B|1978-01-26|1982-06-30|Technicon Instr|Immunoassays using f2 fragments|
    GB2027031A|1978-08-02|1980-02-13|Hoffmann La Roche|Diagnostic Reagent Comprising a Proteinaceous Material Bonded to a Latex|JPS59183369A|1983-04-01|1984-10-18|Kazue Ueno|Latex reagent|
    JPH0541946B2|1983-08-05|1993-06-25|Wako Pure Chem Ind Ltd|
    US4713350A|1983-10-24|1987-12-15|Technicon Instruments Corporation|Hydrophilic assay reagent containing one member of specific binding pair|
    FR2589239B1|1985-10-24|1989-10-20|Cottingham Hugh|AGGLUTINOGRAPHIC REACTION CHAMBER|
    EP0280559B1|1987-02-27|1993-10-20|EASTMAN KODAK COMPANY |Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution|
    JP4486059B2|2006-05-25|2010-06-23|デンカ生研株式会社|Latex composition for immunoassay|
    DK2418486T3|2009-03-05|2013-12-16|Denka Seiken Kk|Test reagent kit and its use in a method for measuring an analyte in test sample|
    KR20140104479A|2011-12-13|2014-08-28|백스터 인터내셔널 인코포레이티드|Measurement of autoantibodies at low conductivity conditions with increased sensitivity|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP56067332A|JPS6367865B2|1981-05-02|1981-05-02|
    [返回顶部]